KR20240130157A - 치료제로서의 펩티드 튜불린 억제제의 펩티드 접합체 - Google Patents

치료제로서의 펩티드 튜불린 억제제의 펩티드 접합체 Download PDF

Info

Publication number
KR20240130157A
KR20240130157A KR1020247020055A KR20247020055A KR20240130157A KR 20240130157 A KR20240130157 A KR 20240130157A KR 1020247020055 A KR1020247020055 A KR 1020247020055A KR 20247020055 A KR20247020055 A KR 20247020055A KR 20240130157 A KR20240130157 A KR 20240130157A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
cancer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247020055A
Other languages
English (en)
Korean (ko)
Inventor
로버트 존 매과이어
요한나 마리 센저리
Original Assignee
싸이브렉사 4, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싸이브렉사 4, 인크. filed Critical 싸이브렉사 4, 인크.
Publication of KR20240130157A publication Critical patent/KR20240130157A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020247020055A 2021-11-17 2022-11-16 치료제로서의 펩티드 튜불린 억제제의 펩티드 접합체 Pending KR20240130157A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163280409P 2021-11-17 2021-11-17
US63/280,409 2021-11-17
PCT/US2022/079973 WO2023091957A1 (en) 2021-11-17 2022-11-16 Peptide conjugates of peptidic tubulin inhibitors as therapeutics

Publications (1)

Publication Number Publication Date
KR20240130157A true KR20240130157A (ko) 2024-08-28

Family

ID=84799580

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247020055A Pending KR20240130157A (ko) 2021-11-17 2022-11-16 치료제로서의 펩티드 튜불린 억제제의 펩티드 접합체

Country Status (14)

Country Link
US (1) US20230416331A1 (enExample)
EP (1) EP4433095A1 (enExample)
JP (1) JP2024542212A (enExample)
KR (1) KR20240130157A (enExample)
CN (1) CN118574642A (enExample)
AU (1) AU2022390891A1 (enExample)
CA (1) CA3243300A1 (enExample)
CL (1) CL2024001486A1 (enExample)
CO (1) CO2024007413A2 (enExample)
IL (1) IL312884A (enExample)
MX (1) MX2024005938A (enExample)
PE (1) PE20242180A1 (enExample)
TW (1) TW202330015A (enExample)
WO (1) WO2023091957A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220052918A (ko) 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
PH12022550037A1 (en) 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2399267T3 (es) * 2005-01-18 2013-03-27 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Suministro selectivo de moléculas al interior de las células o marcación de células en zonas enfermas de tejidos usando un péptido transmembrana sensible a su entorno
JP6262768B2 (ja) * 2013-01-03 2018-01-17 セルトリオン， インク． 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物
WO2018023098A1 (en) * 2016-07-29 2018-02-01 Memorial Sloan Kettering Cancer Center Radiolabeled ligands for targeted pet/spect imaging and methods of their use
KR20220052918A (ko) * 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
PH12022550037A1 (en) * 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics

Also Published As

Publication number Publication date
CN118574642A (zh) 2024-08-30
EP4433095A1 (en) 2024-09-25
CL2024001486A1 (es) 2024-11-29
AU2022390891A1 (en) 2024-06-06
PE20242180A1 (es) 2024-11-07
TW202330015A (zh) 2023-08-01
US20230416331A1 (en) 2023-12-28
IL312884A (en) 2024-07-01
CA3243300A1 (en) 2023-05-25
CO2024007413A2 (es) 2024-11-18
WO2023091957A1 (en) 2023-05-25
MX2024005938A (es) 2024-08-14
JP2024542212A (ja) 2024-11-13

Similar Documents

Publication Publication Date Title
JP7673041B2 (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
TWI820077B (zh) 治療涉及酸性或缺氧性患病組織之疾病之化合物、組合物及方法
JP7013389B2 (ja) 大環状インドール誘導体
CN118878461A (zh) Pd-1/pd-l1抑制剂
EP4225446A1 (en) Modulators of cystic fibrosis transmembrane conductance regulator
TW201726606A (zh) 作為免疫調節劑之化合物
JP2022541749A5 (enExample)
US12234212B2 (en) Peptide conjugates of microtubule-targeting agents as therapeutics
CN107787323A (zh) 用于抑制shp2活性的化合物和组合物
CN110545853A (zh) Raf降解偶联化合物
TW201808957A (zh) 巨環吲哚衍生物
US20230416331A1 (en) Peptide conjugates of peptidic tubulin inhibitors as therapeutics
TW202521546A (zh) 多藥連接體及抗體藥物偶聯物
WO2024153185A1 (zh) 包含bcl-2家族蛋白降解剂的抗体药物偶联物及其制备方法和用途
JP7755347B2 (ja) 腎癌の標的治療のための新規化合物及び組成物
KR20250123213A (ko) 선택적 bet 억제제 및 이의 용도
WO2022222911A1 (zh) 嘧啶酮化合物及其用途
EA051761B1 (ru) Пептидные конъюгаты агентов, нацеленных на микротрубочки, в качестве терапевтических средств
WO2025153015A2 (zh) 一种蛋白翻译抑制剂的偶联物及其用途
WO2022155172A1 (en) Peptide conjugates of therapeutics
HK40005106B (zh) 大环吲哚衍生物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000